Nooglutyl (Nooglutil)
EmergingObscure Russian glutamate-axis nootropic — N-(5-hydroxynicotinoyl)-L-glutamic acid, developed at the Zakusov State Institute… | Pharmaceutical · Oral
Aliases (10)
▸Brand options4 known
StatusRussian Rx (cerebrovascular insufficiency, MCI, post-stroke cognitive recovery indication per Russian Pharmacological Committee dossier). Unscheduled in US (no FDA registration, no DEA scheduling). Not on EU register. Not on WADA prohibited list. Not a DSHEA-eligible dietary ingredient. Effectively gray-market or specialty Russian-import-only outside CIS.
▸ Overview TL;DR
Obscure Russian glutamate-axis nootropic — N-(5-hydroxynicotinoyl)-L-glutamic acid, developed at the Zakusov State Institute (Voronina/Seredenin lineage), Russian Rx for cerebrovascular insufficiency. Claimed dual AMPA + NMDA modulation with neuroprotective profile. Entire human evidence base is Russian-only and effectively single-institution; no Western RCTs; sourcing is harder than noopept; mechanism is mostly redundant with compounds Dylan already has on his V5 plan (Semax + Adamax + Bromantane). For Dylan: NOT-RELEVANT, LOW confidence — sparse data + redundant role + harder sourcing path. Not worth the slot.
▸ Mechanism of action
Nooglutyl is the glutamic acid conjugate of 5-hydroxynicotinic acid — structurally a hybrid of an excitatory amino acid (glutamate, the principal CNS excitatory neurotransmitter and the substrate-side for AMPA + NMDA receptors) and a niacin-derivative (5-hydroxynicotinic acid, which has weak vascular and metabolic activity in its own right). The Russian rationale for this molecular design is that the glutamate moiety provides synaptic-plasticity / glutamatergic activity while the hydroxynicotinoyl moiety provides cerebrovascular / metabolic support — "balance of cerebral metabolic and plasticity processes" (CMP/PMP balance, in the Russian neuropharmacology framing).
1. AMPA receptor modulation (claimed primary). Russian preclinical literature characterizes nooglutyl as a positive modulator at AMPA receptors — broadly similar in mechanism class to racetams and noopept's AMPA arm. Effect magnitude is not well-quantified outside the Zakusov institutional ecosystem. The mechanism is consistent with the rapid cognitive effects reported in Russian clinical use.
2. NMDA receptor modulation (claimed secondary). Less mechanistically clear. Some Russian sources describe partial NMDA modulation — possibly at the glycine co-agonist site or via polyamine-site interactions — yielding a neuroprotective profile against glutamate excitotoxicity. The glutamate-conjugate structure is unusual: delivering an excitatory amino acid as part of a prodrug-like compound creates the apparent paradox of neuroprotection-via-excitatory-substrate, which Russian researchers explain via the modulator-not-direct-agonist framing. Mechanism is plausible but not rigorously characterized in Western-EBM terms.
3. Neuroprotection (claimed clinical mechanism). Russian studies report reduced neuronal damage in ischemia-reperfusion models, reduced cognitive deficit after experimental stroke, and protection against glutamate-induced excitotoxicity. Mechanism is interpreted as the combination of AMPA/NMDA modulation + 5-hydroxynicotinoyl vascular component + general antioxidant action.
4. Cerebrovascular component. The 5-hydroxynicotinoyl moiety is structurally related to niacin and is claimed to contribute mild vasodilation / cerebrovascular flow improvement. This is the basis for the Russian indication in cerebrovascular insufficiency — a category of disease that maps roughly onto Western diagnoses like vascular cognitive impairment, post-stroke cognitive deficit, and chronic cerebral ischemia.
Pharmacokinetics: Limited published data outside Russian sources. Oral bioavailability appears moderate; tmax approximately 1–2 hours; half-life and elimination profile not well-characterized in English-language literature.
▸ Pharmacokinetics No data
▸Quality indicators4 checks
▸ What to expect Generic
- 1Day 1PK-driven acute peak per administration. Verify dose tolerated.
- 2Week 1Steady-state reached for most daily-dosed pharma.
- 3Week 2-4Therapeutic effect established; titration window if needed.
- 4Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
▸ Side effects + safety
- Per Russian sources: Minimal documented adverse effects at therapeutic doses. Occasional mild GI upset, mild headache, mild irritability — generic nootropic-class side effects.
- Western pharmacovigilance signal: Effectively zero (compound is essentially unused outside Russia).
- Rare-serious: No published case reports of serious adverse events. But absence of evidence here is partly absence of exposure — population-scale safety data does not exist.
- Specific watch periods: N/A (no Western clinical use).
Honest framing: Side-effect profile appears clean from Russian sources but the Western evidence base is too thin to make confident safety statements at the population level.
▸Interactions5 compounds
- Citicoline / Alpha-GPCSynergistic(Dylan's V4): Generic choline cofactor for any AMPA/cholinergic-adjacent nootropic. Probably useful but not specifically studied with nooglutyl.
- CerebrolysinSynergistic(Dylan's V5 quarterly): Different mechanism (peptide trophic) — theoretical synergy on the neuroprotective axis. No specific Russian co-prescription data.
- NoopeptAvoidSignificant mechanism overlap (AMPA modulation + neuroprotective framing). Stacking the two is mechanism-redundant. Pick one.
- Multiple racetams simultaneouslyAvoidSame logic — partial AMPA + cholinergic mechanism overlap, diminishing returns.
- NMDA antagonists / dissociativesAvoidTheoretical pharmacological antagonism with the NMDA-modulator arm. Not empirically studied.
▸References6 sources
Voronina TA et al. — Zakusov Institute nooglutyl pharmacology papers
foundational animal pharmacology, Russian-language primary literature with English abstracts.
Seredenin SB et al. — Zakusov Institute conceptual framing of CMP/PMP balance and Russian nootropic class
institutional context for the Russian nootropic taxonomy.
Russian Pharmacological Committee — Nooglutyl marketing authorization dossier
basis for Russian Rx authorization in cerebrovascular insufficiency.
RUPharma — Nooglutyl product page (when in stock)
primary gray-market source, intermittent availability.
CosmicNootropic — Nooglutyl product page (when in stock)
backup gray-market source.